XLXiang Li

Xiang Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xiang Li has a total of 51 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Discovery of amyloid binders as chemical chaperone to block pathological α-synuclein aggregation in synucleinopathies

    by Li Tan, Cheng Yan, Qinyang He, Shenqing Zhang, Chunting Qi, Huaijiang Xiang, Youqi Tao, Kun Shi, Yunxia Li, Kaien Liu, et al.

    The prion-like propagation and accumulation of pathogenic α-synuclein (α-syn) aggregates in the central nervous system are central drivers of Parkinson’s disease (PD) and related synucleinopathies, and remain an important therapeutic target. However, most reported anti-fibrillogenesis agents show limited efficacy in cells or in vivo, and their mechanisms are often poorly defined. Here, we report the unexpected finding that Pittsburgh compound B (PiB), the first clinically used amyloid tracer, selectively suppresses α-syn aggregation. Using an optimized PiB analog, HQY1027, we demonstrate that these compounds function as chemical chaperones. By directly binding polymorphic α-syn fibrils, they remodel the fibril surface and enhance Hsp40 recognition of fibril cores, thereby suppressing fibril formation both in vitro and in cells. HQY1027 is highly effective in neuronal models and significantly reduced α-syn aggregate propagation and motor deficits in a PD mouse model. Our findings establish a chemical chaperone strategy for targeting pathogenic α-syn and identify HQY1027 as a promising therapeutic lead for synucleinopathies. These results further highlight the potential of phenotype-based discovery and optimization of fibril-binding ligands to target intractable protein aggregates in neurodegenerative disorders.

  • Dopamine-Induced Tau Modification Prevents Pathological Phosphorylation and Generates a Distinct Fibril Polymorph

    by Zhengtao Liu, Xiang Li, Qianwen Wang, Kaien Liu, Wen Zeng, Danni Li, Kun Zhao, Yeyang Ma, Houfang Long, Shengnan Zhang, et al.

    Amyloid aggregation of tau is the key pathological event in various tauopathies including Alzheimer's and Pick's disease. Recently, dopamination was identified to modify tau on cysteine, which protects against tau pathology, yet its structural and functional consequences remain unclear. Here, we show that dopamination of the three-repeat (3R) tau fragment K19 alleviates disease-associated tau phosphorylation and alters the tau fibril structure. Solution NMR analysis reveals that dopamine modification at Cys322 of tau suppresses phosphorylation at several pathogenic sites across the microtubule-binding region. Dopaminated tau also exhibited greatly diminished fibrillization in vitro and reduced seeding activity in cells. Finally, we determined the cryo-EM structure of dopaminated tau fibrils at 3.55 Å resolution, revealing a unique fibril polymorph with the smallest core region reported to date for tau. The dopaminated fibril core comprises only 11 residues (centered on the VQIVYK motif) and is stabilized by a minimal hydrophobic interface, explaining its decreased stability compared to that of unmodified tau fibrils. Our results provide atomic-level insight into how dopamine modification imparts a protective effect on tau and underscore the profound influence of post-translational modifications in modulating amyloid protein structure and pathology.


  • Open Access

    De novo design of protein binders to stabilize monomeric TDP-43 and inhibit its pathological aggregation

    by Gangyu Sun, Xiang Li, Jiaojiao Hu, Tianbin Yang, Cong Liu, Zhizhi Wang, Dan Li, Wenqing Xu

    Pathological aggregation of transactive response DNA binding protein of 43 kDa (TDP-43), primarily driven by its low-complexity domain, is closely associated with various neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). Despite the therapeutic potential of preventing TDP-43 aggregation, no effective small molecule or biomacromolecule therapeutics have been successfully developed so far. Here, we introduce a protein design strategy that yields de novo designed proteins capable of stabilizing the key amyloidogenic region of TDP-43 in its native helical conformation with nanomolar binding affinity. The binding mechanism was further characterized by the NMR and mutagenesis study. More importantly, we demonstrated that our designed protein binders efficiently reduced TDP-43 amyloid aggregation both in vitro and in cells. Our work provides a strategy for designing protein stabilizer of the native conformation of pathological proteins for preventing its amyloid aggregation, shedding light on the development of potential therapeutic approaches for ALS, FTLD, and other protein aggregation-associated diseases.


  • Open Access

    Single‐Molecule Insight Into α‐Synuclein Fibril Structure and Mechanics Modulated by Chemical Compounds

    by Xiang Li, Lulu Bi, Shenqing Zhang, Qianhui Xu, Wencheng Xia, Youqi Tao, Shaojuan Wu, Yanan Li, Weidong Le, Wenyan Kang, et al.

    α‐Syn fibrils, a key pathological hallmark of Parkinson's disease, is closely associated with disease initiation and progression. Several small molecules are found to bind or dissolve α‐syn fibrils, offering potential therapeutic applications. Here, an innovative optical tweezers‐based, fluorescence‐combined approach is developed to probe the mechanical characteristics of α‐syn fibrils at the single‐molecule level. When subjected to axial stretching, local deformation within α‐syn fibrils appeared at forces above 50 pN. These structural alternations occurred stepwise and are irreversible, suggesting unfolding of individual α‐syn molecules or subdomains. Additionally, α‐syn fibrils exhibits high heterogeneity in lateral disruption, with rupture force ranging from 50 to 500 pN. The impact of different compounds on the structure and mechanical features of α‐syn fibrils is further examined. Notably, epigallocatechin gallate (EGCG) generally attenuates the rupture force of fibrils by wedging into the N‐terminal polar groove and induces fibril dissociation. Conversely, copper chlorophyllin A (CCA) attaches to four different sites wrapping around the fibril core, reinforcing the stability of the fibril against rupture forces. The work offers an effective method for characterizing single‐fibril properties and bridges compound‐induced structural alternations with mechanical response. These insights are valuable for understanding amyloid fibril mechanics and their regulation by small molecules.


  • Open Access

    Binding adaptability of chemical ligands to polymorphic α-synuclein amyloid fibrils

    by Kaien Liu, Youqi Tao, Qinyue Zhao, Wencheng Xia, Xiang Li, Shenqing Zhang, Yuxuan Yao, Huaijiang Xiang, Chao Han, Li Tan, et al.

    α-synuclein (α-syn) assembles into structurally distinct fibril polymorphs seen in different synucleinopathies, such as Parkinson’s disease and multiple system atrophy. Targeting these unique fibril structures using chemical ligands holds diagnostic significance for different disease subtypes. However, the molecular mechanisms governing small molecules interacting with different fibril polymorphs remain unclear. Here, we investigated the interactions of small molecules belonging to four distinct scaffolds, with different α-syn fibril polymorphs. Using cryo-electron microscopy, we determined the structures of these molecules when bound to the fibrils formed by E46K mutant α-syn and compared them to those bound with wild-type α-syn fibrils. Notably, we observed that these ligands exhibit remarkable binding adaptability, as they engage distinct binding sites across different fibril polymorphs. While the molecular scaffold primarily steered the binding locations and geometries on specific sites, the conjugated functional groups further refined this adaptable binding by fine-tuning the geometries and binding sites. Overall, our finding elucidates the adaptability of small molecules binding to different fibril structures, which sheds light on the diagnostic tracer and drug developments tailored to specific pathological fibril polymorphs.